Capital
Deals
Financings, M&A, partnerships and public funding with a public source.
Deals by year
Disclosed venture capital by year
Deals by segment
37 deals. Venture $270.8M (13 deals) · M&A $277.1M (4) · Divestiture $135M (1) · Government awards $229.4M (4) · 15 undisclosed. Undisclosed amounts are excluded. Figures marked up to are maximums.
| Counterparties | Source | |||||||
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Polyphron | Venture financing | Seed | $20M | Quiet Capital (lead); Gradient, Haystack, Compound | Engineered & bioprinted tissue | North America | hlth.com(opens in new tab)confirmed |
| Aug 12, 2026 | CN Bio | Grant / non-dilutive | Innovate UK | Undisclosed | Innovate UK | Organ-on-chip & MPS | UK | cn-bio.com(opens in new tab)confirmed |
| Aug 2026 | MIMETAS | M&A | Majority stake | Undisclosed | Bruker (acquirer); InnovationQuarter Capital sold its stake | Organ-on-chip & MPS | Europe | cms.law(opens in new tab)confirmed |
| Jun 30, 2026 | Xellar Biosystems | Venture financing | Series A / A+ | $50M | Not disclosed | Organ-on-chip & MPS | North America | technode.global(opens in new tab)confirmed |
| Jun 18, 2026 | Charles River Laboratories | Partnership | Undisclosed | Lilly TuneLab | AI toxicity & ADMET prediction | North America | ir.criver.com(opens in new tab)confirmed | |
| May 20, 2026 | PhenoVista Biosciences | M&A | Undisclosed | InSphero (acquirer) | NAM CROs & testing services | North America | insphero.com(opens in new tab)confirmed | |
| May 2026 | ProxyBio | Venture financing | Seed | $3.5M | GKCC | Organoids & 3D models | North America | |
| Apr 22, 2026 | Certara | Divestiture | up to $135M | Veristat (buyer) | PBPK, QSP & biosimulation | North America | ir.certara.com(opens in new tab)confirmed | |
| Mar 18, 2026 | NIH Complement-ARIE | Government funding | $150M | NIH Common Fund; FNIH validation network | North America | nih.gov(opens in new tab)confirmed | ||
| Feb 25, 2026 | Charles River (discovery sites) | M&A | $145M | IQVIA (acquirer) | NAM CROs & testing services | Europe | biopharmatrend.com(opens in new tab)confirmed | |
| Jan 2026 | PathoQuest | M&A | Undisclosed; Charles River already held about 21% | Charles River Laboratories (acquirer) | NAM CROs & testing services | Europe | ir.criver.com(opens in new tab)confirmed | |
| Dec 4, 2025 | Inductive Bio | Government funding | ARPA-H CATALYST | up to $21M | ARPA-H; Baylor College of Medicine, Amgen, Torch Bio, Cincinnati Children's | AI toxicity & ADMET prediction | North America | |
| Dec 4, 2025 | Deep Origin | Government funding | ARPA-H CATALYST | up to $31.7M | ARPA-H; PREDICTS consortium incl. Ginkgo Bioworks, Sanford Burnham Prebys, Tessel Biosciences | AI toxicity & ADMET prediction | North America | deeporigin.com(opens in new tab)confirmed |
| Dec 4, 2025 | Revalia Bio (Draper-led team) | Government funding | ARPA-H CATALYST | up to $26.7M | ARPA-H; Draper (team lead), Yale, LifeShare Network | Ex vivo human tissue & organs | North America | |
| Nov 11, 2025 | UK Government | Government funding | GBP 75M package | DSIT, Defra and Home Office | UK | aa.com.tr(opens in new tab)confirmed | ||
| Oct 27, 2025 | BeCytes Biotechnologies | M&A | Undisclosed | BioIVT (acquirer) | iPSC & primary human cells | Europe | businesswire.com(opens in new tab)confirmed | |
| Q4 2025 | DOPPL | M&A | Undisclosed | InSphero (acquirer) | Organoids & 3D models | Europe | genomeweb.com(opens in new tab)reported | |
| Sep 4, 2025 | Revalia Bio | Venture financing | Seed | $14.5M | America's Frontier Fund and Sierra Ventures (co-leads) | Ex vivo human tissue & organs | North America | biospace.com(opens in new tab)confirmed |
| Aug 8, 2025 | Cellbox Labs | Grant / non-dilutive | EUR 3.3M non-dilutive | Organ-on-chip & MPS | Europe | eu-startups.com(opens in new tab)confirmed | ||
| Jun 2025 | Parallel Bio | Venture financing | Series A | $21M | AIX Ventures (lead); Amplo, Marc Benioff, Metaplanet, Humba, Atypical, Undeterred, Jeff Dean | Organoids & 3D models | North America | |
| May 29, 2025 | Vivodyne | Venture financing | Series A | $40M | Khosla Ventures (lead) | Organ-on-chip & MPS | North America | axios.com(opens in new tab)confirmed |
| May 7, 2025 | Inductive Bio | Venture financing | Series A | $25M | Obvious Ventures (lead); a16z Bio + Health, Lux Capital, S32, Character, Amino Collective | AI toxicity & ADMET prediction | North America | biopharmatrend.com(opens in new tab)confirmed |
| Apr 4, 2025 | MatTek | M&A | $80M | Sartorius (acquirer); BICO (seller) | Engineered & bioprinted tissue | North America | sartorius.com(opens in new tab)confirmed | |
| Apr 2025 | Axiom Bio | Venture financing | Seed | $15M | Amplify Partners, Dimension, Zetta Venture Partners | AI toxicity & ADMET prediction | North America | fenwick.com(opens in new tab)confirmed |
| Jan 7, 2025 | Quris-AI | Partnership | Undisclosed | Merck KGaA | Organ-on-chip & MPS | Middle East | owler.com(opens in new tab)reported | |
| Dec 17, 2024 | HUB Organoids | M&A | Undisclosed; closed Dec 23, 2024 | Merck KGaA / MilliporeSigma (acquirer) | Organoids & 3D models | Europe | businesswire.com(opens in new tab)confirmed | |
| Dec 5, 2024 | Newcells Biotech | Venture financing | Series B | Undisclosed | Investors include Mercia and Northstar Ventures (per Tracxn) | Organoids & 3D models | UK | tracxn.com(opens in new tab)reported |
| Nov 19, 2024 | MEPSGEN | Venture financing | Series C | $14.8M | Yuanda Financial Holdings and others (per Tracxn) | Organ-on-chip & MPS | Asia-Pacific | tracxn.com(opens in new tab)reported |
| Nov 8, 2024 | AxoSim | Venture financing | Series A | $3.7M | Organ-on-chip & MPS | North America | tracxn.com(opens in new tab)reported | |
| Oct 29, 2024 | Nortis (Numa Biosciences) | M&A | Undisclosed; asset acquisition | Quris-AI (acquirer) | Organ-on-chip & MPS | North America | globenewswire.com(opens in new tab)confirmed | |
| Jul 9, 2024 | Chemaxon | M&A | Undisclosed in sources reviewed; closed Oct 2, 2024 | Certara (acquirer) | QSAR, read-across & cheminformatics | Europe | nasdaq.com(opens in new tab)confirmed | |
| Apr 23, 2024 | CN Bio | Venture financing | Series B | $21M | Bayland Capital and others | Organ-on-chip & MPS | UK | cn-bio.com(opens in new tab)confirmed |
| Dec 14, 2023 | Applied BioMath | M&A | $36.6M | Certara (acquirer) | PBPK, QSP & biosimulation | North America | certara.com(opens in new tab)reported | |
| Dec 13, 2023 | Inductive Bio | Venture financing | Seed | $4.3M | Andreessen Horowitz and Lux Capital (co-leads) | AI toxicity & ADMET prediction | North America | alleywatch.com(opens in new tab)confirmed |
| Nov 22, 2023 | Vivodyne | Venture financing | Seed | $38M | Khosla Ventures (lead); Bison Ventures, CS Ventures, Kairos Ventures, MBX Capital | Organ-on-chip & MPS | North America | endpts.com(opens in new tab)confirmed |
| Aug 30, 2023 | Instem | M&A | Take-private | About GBP 203M equity value; completed Nov 2023 | ARCHIMED (acquirer) | QSAR, read-across & cheminformatics | UK | rttnews.com(opens in new tab)confirmed |
| Jun 16, 2023 | Immunetrics | M&A | $15.5M | Simulations Plus (acquirer) | PBPK, QSP & biosimulation | North America | sec.gov(opens in new tab)confirmed |